Every material Form 8-K ATOSSA THERAPEUTICS, INC. has filed with the SEC since September 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Atossa Therapeutics entered into a Stapled Contingent Value Rights Agreement with VStock Transfer, LLC, and its board declared one stapled CVR for each common share outstanding at the close of business on October 19, 2026. Holders would receive a share of 25% of net proceeds from the sale or deemed monetization of the company's first qualifying FDA priority review voucher, capped at $50 million, but no voucher has been awarded and payment is not assured.
Record date is October 19, 2026; one stapled CVR per share, with shares issued later also carrying a CVR until detachment or expiration.
Aggregate CVR payments equal 25% of net proceeds from the first qualifying voucher, capped at $50 million, for vouchers awarded on or before December 31, 2036.
No priority review voucher has been awarded, and no marketing application for (Z)-endoxifen has been submitted; the company is not required to pursue approval or sell a voucher.
CVRs do not carry voting or dividend rights and will not trade separately while attached to the shares.
Atossa Therapeutics' board approved a plan to issue one contingent value right (CVR) for each common share, giving shareholders a share of proceeds if the company monetizes its first qualifying rare pediatric disease priority review voucher. No voucher has been awarded and no product candidate has been approved, so no CVR payment is assured.
Each CVR would entitle holders to 25% of net proceeds from a qualifying voucher monetization, capped at $50 million in aggregate payments.
Shareholders of record on a record date to be announced, and shares issued later, would receive one CVR per share.
CVRs would not trade separately and would expire if no qualifying voucher is awarded by December 31, 2036, unless the Board extends that date.
Atossa has previously reported disclosed voucher sales of $100 million to $220 million over the preceding 18–24 months, but past sales do not establish the value of any voucher it might receive.
Atossa Therapeutics made available an updated corporate presentation dated September 18, 2026, furnished under Regulation FD and not deemed filed. The presentation reports $26.1 million in cash and equivalents and no debt at June 30, 2026, and outlines timelines for its (Z)-Endoxifen oncology and rare disease programs.
Cash and cash equivalents of $26.1 million and no debt outstanding at June 30, 2026
Total operating expenses of $8.7 million in Q2 2026; June registered direct offering raised $4.0 million (net)
Up to $12 million additional from Series A and short-term Series B warrants, assuming full cash exercise
EVANGELINE Phase 2 enrollment completed; top-line data anticipated in 4Q26; IND clearance in MAS and DMD anticipated in 2H26
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ATOSSA THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →